Our results also verified that the activity of PI3K/Akt and mTOR signaling pathways increased after gemcitabine treatment, and the stemness of pancreatic cancer decreased after treated with PI3K/Akt and mTOR inhibitors combined with gemcitabine respectively. Here, AKT1 is linked to pancreatic neoplasm.